Latest news with #MerusNV
Globe and Mail
31-07-2025
- Business
- Globe and Mail
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 as New Clinical Trials and Targeted Therapies Reshape Care
Merkel Cell Carcinoma Market Forecast, combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM. The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among healthcare professionals contributing to earlier diagnosis, increasing chronic UV exposure, and the emergence of innovative therapies such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals / AgonOx), KT 253 (Kymera Therapeutics) and others. DelveInsight's latest report, ' Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,' combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034 Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France. Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends. The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM. According to DelveInsight's analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor. Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis Recent Developments: In July 2025, the National Comprehensive Cancer Network published updated guidelines for MCC treatment with several important changes, including ctDNA monitoring, Radiation timing, Hypo-fractionated radiation, and others. In June 2025, the FDA lifted a manufacturing-related partial clinical hold on the phase 3 accelerated approval trial for immune agonist IFx-2.0. The trial evaluates IFx-2.0 as adjunctive therapy versus placebo with pembrolizumab in frontline treatment for patients with advanced or metastatic MCC. In May 2025, a new clinical trial (NCT06940440) began evaluating the innate immune agonist IFx-Hu2.0 in patients with noncutaneous MCC of unknown primary. In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. In April 2025, a multicenter study of 1,049 Merkel Cell Carcinoma patients found that radiation within eight weeks of diagnosis improved survival and reduced disease progression risk by 36%. Surgical margins of 1-2 cm led to better outcomes. At five years, 83% of patients were alive and 64% had no cancer progression, highlighting the importance of timely treatment and appropriate surgery. The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA). The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells. DelveInsight's analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others. Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape. MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight's leading oncology consultant commented, 'As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.' This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth. Table of Contents 1. Key Insights 2. Report Introduction 3. Merkel Cell Carcinoma Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Merkel Cell Carcinoma Background and Overview 7. Merkel Cell Carcinoma Epidemiology and Market Methodology 8. Epidemiology and Merkel Cell Carcinoma Patient Population 9. Merkel Cell Carcinoma Patient Journey 10. Merkel Cell Carcinoma Marketed Therapies 11. Merkel Cell Carcinoma Emerging Drug Profiles 12. MCC: Market Analysis 13. Key Opinion Leaders' Views 14. Merkel Cell Carcinoma Unmet Needs 15. Merkel Cell Carcinoma SWOT Analysis 16. Merkel Cell Carcinoma Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Merkel Cell Carcinoma Pipeline Insight Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others. About DelveInsight DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Yahoo
06-06-2025
- Business
- Yahoo
Why Merus N.V. (MRUS) Crashed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other worst-performing stocks on Wednesday. Merus NV snapped a four-day winning streak on Wednesday, shedding 7.75 percent to end at $57.58 apiece as investors repositioned portfolios following the company's announcement of a $300-million follow-on offering that could result in a potential dilution of their existing equity. According to the company, it aims to sell 5.26 million common shares at a price of $57 apiece. It also granted its underwriters a 30-day option to purchase up to 789,473 common shares. A scientist looking through a microscope conducting research in an immuno-oncology lab. According to the company, it plans to use the proceeds to ramp up the clinical development of its product candidates, while the balance will be allocated for preclinical research and technology development, working capital, and general corporate purposes. Merus N.V. (NASDAQ:MRUS) tapped Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital as its acting joint book-runners for the offering. Meanwhile, Van Lanschot Kempen will act as lead manager for the offering. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
BMO Capital Markets maintained its Outperform rating on Merus N.V. (NASDAQ:MRUS) shares on May 24 while raising its price target from $96 to $110. The revision comes after encouraging Phase 2 data for Merus' drug candidates petosemtamab and pembrolizumab (pembro) were released. The drugs are intended to treat recurrent or metastatic Head and neck squamous cell carcinoma (HNSCC). Presented at the American Society of Clinical Oncology (ASCO), Merus' updated data included findings from an analysis of 43 evaluable patients conducted on February 27, 2025. With a confirmed Objective Response Rate (ORR) of 63%, the study demonstrated robust and long-lasting responses. Notably, a 79% survival rate was shown by the 12-month Overall Survival data. The standard of care for pembrolizumab, which carries a reported survival rate of roughly 50–59%, compares favorably to this. The market's response to the ASCO presentation indicates that petosemtamab's clinical potential to take the HNSCC treatment landscape to new heights is well-supported. The price target increase and revised estimates also demonstrate growing investor confidence in the drug's prospects. Evan David Seigerman of BMO Capital backed this assessment after the approval probability rose from 85% to 90%, pointing to favorable safety data. While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data
BMO Capital Markets maintained its Outperform rating on Merus N.V. (NASDAQ:MRUS) shares on May 24 while raising its price target from $96 to $110. The revision comes after encouraging Phase 2 data for Merus' drug candidates petosemtamab and pembrolizumab (pembro) were released. The drugs are intended to treat recurrent or metastatic Head and neck squamous cell carcinoma (HNSCC). Presented at the American Society of Clinical Oncology (ASCO), Merus' updated data included findings from an analysis of 43 evaluable patients conducted on February 27, 2025. With a confirmed Objective Response Rate (ORR) of 63%, the study demonstrated robust and long-lasting responses. Notably, a 79% survival rate was shown by the 12-month Overall Survival data. The standard of care for pembrolizumab, which carries a reported survival rate of roughly 50–59%, compares favorably to this. The market's response to the ASCO presentation indicates that petosemtamab's clinical potential to take the HNSCC treatment landscape to new heights is well-supported. The price target increase and revised estimates also demonstrate growing investor confidence in the drug's prospects. Evan David Seigerman of BMO Capital backed this assessment after the approval probability rose from 85% to 90%, pointing to favorable safety data. While we acknowledge the potential of MRUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRUS and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None.
